• to lower the risk of significant cardiovascular (coronary heart and blood vessel) issues in Grown ups with style 2 diabetes and heart problemsThis led Novo Nordisk to carry out further more investigation into higher dosages of semaglutide specifically for weight management.These recommendations recommend GLP-one agonists as a further treatment